FAQ: Personalizing CLL Tx
Application of Individualized Treatment for CLL/SLL: Novel Agents, Combinations, and Sequencing Therapy: FAQ

Released: December 23, 2020

Expiration: December 22, 2021

Jeremy S. Abramson
Jeremy S. Abramson, MD, MMSc
Brian T. Hill
Brian T. Hill, MD, PhD
William G. Wierda
William G. Wierda, MD, PhD

Activity

Progress
1
Course Completed

In this episode, William G. Wierda, MD, PhD; Jeremy S. Abramson, MD, MMSc; and Brian Hill, MD, PhD; answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.

Presenters:

William G. Wierda, MD, PhD, Program Director
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio